Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
Completed · Phase 3 · Has a placebo group
Conditions studied: Schizophrenia
In brief
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR short term among acutely psychotic patients with chronic schizophrenia.
Key facts
- Study ID
- NCT00790192
- Run by
- Sumitomo Pharma America, Inc.
- People needed
- 488
- Starts
- 2008-10-01
- Expected to finish
- 2010-07-01
- Last updated by the study team
- 2016-03-17
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Provide written informed consent and aged between 18 and 75 years of age.
- Meets DSM-IV™ criteria for a primary diagnosis of schizophrenia.
- Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.
- Able and agrees to remain off prior antipsychotic medication for the duration of study.
- Good physical health on the basis of medical history, physical examination, and laboratory screening.
- Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.
You may not qualify if…
- Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
- Any chronic organic disease of the CNS (other than schizophrenia).
- Used investigational compound within 30 days.
- Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.
Where it is running
- Woodland International Research Group — Little Rock, Arkansas, United States
- Clinical Pharmacological Studies, Inc. — Cerritos, California, United States
- Comprehensive Neuroscience, Inc — Cerritos, California, United States
- Clinical Innovations, Inc. — Costa Mesa, California, United States
- Synergy Escondido — Escondido, California, United States
- Collaborative Neuroscience Network — Garden Grove, California, United States
- Apostle Clinical Trials, Inc. — Long Beach, California, United States
- California Clinical Trials — Paramount, California, United States
- Pasadena Research Institute — Pasadena, California, United States
- CNRI-Los Angeles. LLC — Pico Rivera, California, United States
- Clinical Innovations, Inc. — Riverside, California, United States
- CNRI-San Diego — San Diego, California, United States
- UCSD Medical Center — Sandeigo, California, United States
- Segal Institute for Clinical Research — Highlands Ranch, Colorado, United States
- Comprehensive Neuroscience, Inc. — Washington D.C., District of Columbia, United States
- Florida Clinical Research Center — Bradenton, Florida, United States
- Florida Clinical Research Center, LLC — Fruitland Park, Florida, United States
- Lake Charles Clinical Trials — Lake Charles, Louisiana, United States
- Booker, J. Gary, MD. APMC — Shreveport, Louisiana, United States
- Precise Clinical Research — Flowood, Mississippi, United States
- St. Charles Psychiatric Associates — Saint Charles, Missouri, United States
- St. Louis Research, Inc. — St Louis, Missouri, United States
- CRI Worldwide — Willingboro, New Jersey, United States
- Comprehensive Neuroscience, Inc — Holliswood, New York, United States
- K&S Professional Research Services, LLC — Little Rock, Arkansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.